Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | OGT | O15294 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667623 | 0.86 | IL4I1 (0.39) | IL4I1HPGDNOS1MAPTMEN1 | |
| SCHEMBL31667612 | 0.86 | IL4I1 (0.39) | IL4I1HPGDNOS1MAPTMEN1 | |
| SCHEMBL31667029 | 0.86 | IL4I1 (0.37) | IL4I1HPGDNOS1MAPTMEN1 | |
| SCHEMBL31667349 | 0.86 | IL4I1 (0.39) | IL4I1HPGDNOS1MAPTMEN1 | |
| SCHEMBL31667297 | 0.85 | IL4I1 (0.38) | IL4I1HPGDNOS1MAPTMEN1 | |
| SCHEMBL31666968 | 0.84 | IL4I1 (0.44) | IL4I1HPGDNOS1MAPTMEN1 | |
| SCHEMBL31667330 | 0.83 | IL4I1 (0.37) | IL4I1HPGDNOS1MAPTMEN1 | |
| SCHEMBL31667717 | 0.83 | MEN1 (0.45) | IL4I1HPGDMAPTMEN1KMT2A | |
| SCHEMBL31666930 | 0.83 | MEN1 (0.45) | IL4I1HPGDMAPTMEN1KMT2A | |
| SCHEMBL31667679 | 0.83 | MEN1 (0.45) | IL4I1HPGDMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | IL4I1 2872/4885HPGD 520/4885NOS1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.